|
GSK accused of RLS drug contract breach by Xenoport
Pharma Times The USA's Xenoport is threatening to end its alliance with GlaxoSmithKline for the restless legs syndrome drug Horizant, after claiming the drugs major is not doing enough to market the treatment. Horizant (gabapentin enacarbil) extended-release … |
View full post on restless leg syndrome – Google News
